Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies

Hakan Inan, Shuqi Wang, Fatih Inci, Murat Baday, Richard Zangar, Sailaja Kesiraju, Karen Anderson, Brian T. Cunningham, Utkan Demirci

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.

    Original languageEnglish (US)
    Article number3322
    JournalScientific Reports
    Volume7
    Issue number1
    DOIs
    StatePublished - Dec 1 2017

    Fingerprint

    Tumor Biomarkers
    Papillomavirus Infections
    Lab-On-A-Chip Devices
    Neoplasms
    Immunoassay
    Antibodies
    Primary Health Care
    Penile Neoplasms
    Vulvar Neoplasms
    Oropharyngeal Neoplasms
    Technology
    Oncogene Proteins
    Uterine Cervical Neoplasms
    Anti-Idiotypic Antibodies
    Carcinogenesis
    Cell Proliferation
    Biopsy

    ASJC Scopus subject areas

    • General

    Cite this

    Inan, H., Wang, S., Inci, F., Baday, M., Zangar, R., Kesiraju, S., ... Demirci, U. (2017). Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. Scientific Reports, 7(1), [3322]. https://doi.org/10.1038/s41598-017-02672-6

    Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. / Inan, Hakan; Wang, Shuqi; Inci, Fatih; Baday, Murat; Zangar, Richard; Kesiraju, Sailaja; Anderson, Karen; Cunningham, Brian T.; Demirci, Utkan.

    In: Scientific Reports, Vol. 7, No. 1, 3322, 01.12.2017.

    Research output: Contribution to journalArticle

    Inan, H, Wang, S, Inci, F, Baday, M, Zangar, R, Kesiraju, S, Anderson, K, Cunningham, BT & Demirci, U 2017, 'Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies' Scientific Reports, vol. 7, no. 1, 3322. https://doi.org/10.1038/s41598-017-02672-6
    Inan, Hakan ; Wang, Shuqi ; Inci, Fatih ; Baday, Murat ; Zangar, Richard ; Kesiraju, Sailaja ; Anderson, Karen ; Cunningham, Brian T. ; Demirci, Utkan. / Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
    @article{f76f8dc66ed34576b4c89dc6a26fb417,
    title = "Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies",
    abstract = "Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.",
    author = "Hakan Inan and Shuqi Wang and Fatih Inci and Murat Baday and Richard Zangar and Sailaja Kesiraju and Karen Anderson and Cunningham, {Brian T.} and Utkan Demirci",
    year = "2017",
    month = "12",
    day = "1",
    doi = "10.1038/s41598-017-02672-6",
    language = "English (US)",
    volume = "7",
    journal = "Scientific Reports",
    issn = "2045-2322",
    publisher = "Nature Publishing Group",
    number = "1",

    }

    TY - JOUR

    T1 - Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies

    AU - Inan, Hakan

    AU - Wang, Shuqi

    AU - Inci, Fatih

    AU - Baday, Murat

    AU - Zangar, Richard

    AU - Kesiraju, Sailaja

    AU - Anderson, Karen

    AU - Cunningham, Brian T.

    AU - Demirci, Utkan

    PY - 2017/12/1

    Y1 - 2017/12/1

    N2 - Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.

    AB - Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.

    UR - http://www.scopus.com/inward/record.url?scp=85020703642&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85020703642&partnerID=8YFLogxK

    U2 - 10.1038/s41598-017-02672-6

    DO - 10.1038/s41598-017-02672-6

    M3 - Article

    VL - 7

    JO - Scientific Reports

    JF - Scientific Reports

    SN - 2045-2322

    IS - 1

    M1 - 3322

    ER -